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Inhaled sGC Modulator Can Lower PH in Patients With
COPD Without Deteriorating Oxygenation
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This study uses a highly fidelity computational simulator of pulmonary physiology to evaluate the impact of a soluble
guanylate cyclase (sGC) modulator on gas exchange in patients with chronic obstructive pulmonary disease (COPD) and
pulmonary hypertension (PH) as a complication. Three virtual patients with COPD were configured in the simulator based on
clinical data. In agreement with previous clinical studies, modeling systemic application of an sGC modulator results in
reduced partial pressure of oxygen (PaO2) and increased partial pressure of carbon dioxide (PaCO2) in arterial blood, if a
drug-induced reduction of pulmonary vascular resistance (PVR) equal to that observed experimentally is assumed. In
contrast, for administration via dry powder inhalation (DPI), our simulations suggest that the treatment results in no
deterioration in oxygenation. For patients under exercise, DPI administration lowers PH, whereas oxygenation is improved
with respect to baseline values.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 A modulator of sGC has recently been shown in a
clinical study to improve pulmonary hemodynamics in
patients with COPD and PH as a complication. How-
ever, systemic administration of sGCs bears a high
risk of deterioration of V/Q mismatch due to relief of
hypoxic vasoconstriction.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We aim to identify if administration of an sGC via
DPI, instead of systemically, could reduce the nega-
tive impact of the drug on oxygenation.
WHAT DOES THIS STUDYADD TOOUR KNOWLEDGE?
 Using a high-fidelity pulmonary simulator, cali-
brated to data from three patients with COPD involved
in a previous clinical trial, we showed that administer-
ing an sGC via DPI can reduce PH without deteriorat-
ing oxygenation, particularly when administration is
combined with exercise.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 Our results highlight the potential advantages of
administering sGCs to patients via DPI, rather than
systemically.
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality in most coun-
tries.1,2 The World Health Organization estimates that
COPD was the fifth leading cause of death in high-income
countries in 2001, and it was the sixth leading cause of
death in nations of low and middle income.3 COPD has
been identified as a major global health burden based on
its high prevalence and significant healthcare costs.4,5
A serious complication of COPD is pulmonary hypertension
(PH), a progressive and debilitating condition associated with
a sustained increase in mean pulmonary artery pressure
(mPAP) that results from excessive vasoconstriction and
remodeling of the pulmonary arteries.6 It is associated with
shorter survival and has been seen as a predictive factor for
worse clinical outcomes and frequent use of health resour-
ces.7,8 Accordingly, there has been significant interest in
exploring PH-specific therapies in patients with COPD. Vari-
ous vasodilating drugs with different modes of action
have been investigated in clinical studies.9 Most of these
studies considered systemic applications (oral administration),
although some also considered administration via inhala-
tion. Generally, these studies aimed for a dilation or
relaxation of the pulmonary arterial vessels, thus lower-
ing pulmonary vascular resistance. On the other hand,
unselective vasodilation of pulmonary vessels may also
lead to a relief of hypoxic vasoconstriction in low-ventilat-
ing/non-ventilating areas of the lung, and consequently to
increased ventilation-perfusion (V/Q) mismatch and a
deterioration of oxygenation.
One of the most extensively investigated drugs in COPD-
PH is the phosphodiesterase-5 (PDE-5) inhibitor sildena-
fil.10–15 When given systemically (i.e., oral or intravenous
administration) in acute studies sildenafil consistently
resulted in a reduction of mPAP and an improvement of
exercise capacity and 6-minute walking distance.10,12,13
Although, during exercise there seems to be no adverse
reaction, at rest the hemodynamic changes occurred at the
expense of worsening gas exchange due to increased V/Q
mismatching.13 In chronic studies, no clear positive effect
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of the treatment with sildenafil, as compared to placebo,
could be observed with positive14 as well as negative out-
comes being reported.11,15
Trials have also been undertaken with bosentan, an oral
endothelin receptor antagonist, in treating PH in COPD. Stolz
et al.16 found in patients with severe COPD that those treated
with bosentan incurred a decreased quality of life, worsening
arterial oxygen saturation, and an increased alveolar-arterial
gradient with no change in exercise capacity. In another
study, the treatment group benefited from significant
improvements in mPAP, pulmonary vascular resistance
(PVR), and the 6-minute walk distance without a significant
decline in oxygenation.17
Inhalation therapy was investigated in patients with COPD-
PH with inhaled nitrogen oxide (iNO)18–25 and the prostacyclin
analogue iloprost.26–28 The trials with iNO consistently demon-
strated a considerable and concentration-dependent reduction
of PVR.18–23,25 The response of gas exchange, in particular of
oxygenation, to iNO therapy is, however, heterogeneous.
Although, clear concentration dependence cannot be derived
from the different studies, there is at least evidence that at lower
iNO concentrations arterial oxygenation is improved or remains
unchanged with iNO inhalation,18,21,23,25 whereas at higher
concentrations (>20 ppm) there is no gain in oxygenation22 or
even a deterioration.19,20 The latter response is presumably the
result of increased V/Q mismatch caused by nitrogen oxide
releasing hypoxic vasoconstriction in poorly ventilated regions
of the lungs. However, the opposite effect was also observed in
another study, in which an improvement of partial pressure of
oxygen (PaO2) was recorded with high nitrogen oxide
concentrations.18
An inconsistent picture also emerges from the studies
with inhaled iloprost. Although Boeck and colleagues26 did
not find positive effects but instead a worsening of gas
exchange for two different iloprost doses in a cross-over
study, two other studies reported improvements in V/Q
matching, gas exchange, and exercise tolerance.27,28
Recently, riociguat, a stimulator of soluble guanylate syn-
thase (sGC) has been approved for treatment of pulmonary
arterial hypertension and chronic thromboembolic PH after
it showed improved 6-minute walk distance, compared with
placebo, and also improved PVR, functional class, dyspnea,
and health-related quality of life in these diseases.29,30 rio-
ciguat was also investigated in a single dose study with
patients with COPD with borderline or manifest PH (mPAP
23 mmHg).31 Similar as for other therapies, significant
reductions of mPAP and PVR could be demonstrated in
this patient population. Although some reduction in oxygen-
ation occurred with orally administered riociguat in these
studies, this was not at levels that were judged to be clini-
cally relevant.
Overall, the results from the different studies discussed
above give rise to conclusions that:
• The pharmacological principle of vasodilation is generally appropriate
for improving pulmonary hemodynamics and exercise tolerance of
patients with COPD-PH;
• Systemic administration of drugs bears a high risk of deterioration of
V/Q mismatch due to relief of hypoxic vasoconstriction;
• Inhaled administration shows positive effects and may, in contrast to
systemic administration, lead to improved V/Q mismatching, although
also the opposite can happen if the distribution of the drug is not
strictly limited to well ventilated regions of the lungs, or if alveolar
absorption is high and considerable systemic exposure occurs after
inhalation.
One potential limitation to consider is the fact that inhala-
tion with a metered dose or dry powder inhalation (DPI),
typically used in lung diseases, such as COPD and
asthma,32,33 is associated with a deep breath. This could,
however, deteriorate the advantage of inhaled administra-
tion, as a deep breath may result in drug particles being
deposited in lung areas that are not ventilated at rest.
The complexity of the findings summarized above highlights
the fact that the role of different therapies and corresponding
administration methods in COPD-related PH needs further
exploration. In this study, simulation approaches using a high-
fidelity simulation model were adopted to evaluate the effects
of a vasodilator, in terms of hemodynamics and oxygenation,
in patients with COPD with PH.
In the following, we demonstrate that the simulation
model is able to recapitulate observed changes in gas
exchange after systemic administration of the sGC stimula-
tor riociguat, based on the experimentally determined
reductions of PVR. Thus validated, the model is then used
to evaluate the effects of alternative administration methods
(DPI via a deep breath and inhalation via normal breathing;
e.g., using a ventilator) of the drug. We also quantitatively
investigate the consequences of administering the drug to
patients while they are under exercise.
METHODS
Pulmonary simulator
The simulator used in this study is a multicompartmental
computational model that uses an iterative technique to
simulate integrated respiratory and cardiovascular patho-
physiological scenarios.34–38 In contrast to previous models
of COPD pathophysiology that included only two or three
alveolar compartments,39 our model allows the user to
define up to several hundred individual compartments
(each with its own individual mechanical characteristics) to
be implemented in the simulation. Each of these alveolar
compartments has a unique and configurable bronchiolar
resistance, PVR, stiffness index, and extrinsic pressure.
The ability to adjust these parameters individually across all
alveolar compartments allows the model to recreate the
heterogeneous effects of COPD on the overall physiology
of the lungs. The model also includes specific equations to
represent the effects of alveolar collapse, threshold opening
pressure, alveolar stiffening, and airway obstruction. The
net effect of these components of the simulation is that the
defining, clinical features of COPD may be observed in the
model: alveolar gas trapping (with intrinsic positive end-
expiratory pressure), collapse-reopening of alveoli (with
gradual reabsorption of trapped gas if reopening does not
occur), limitation of expiratory flow, and increased functional
residual. A complete description of the simulator, including
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all underlying equations, is provided in the Supplementary
File.
Model matching to patient data
The model was matched to individual patient data by using
a global optimization algorithm,40 as described in preceding
publications,35,36 and in the Supplementary File. For the
present work, we matched the pulmonary simulator to the
characteristics of three patients with COPD-PH with differ-
ing gas exchange properties, which were included in the
previous study with riociguat.31 The respective data on
PaO2, partial pressure of carbon dioxide (PaCO2), dead
space fraction, and V/Q at baseline (see Table 1) were
taken from the study report. The three example datasets
were chosen in order to cover a wide spectrum of COPD
pathophysiology. For two of the patients, the multiple inert
gas elimination technique was applied in order to determine
data on V/Q mismatch, and, thus, for these patients we
also present a comparison of data and model outputs on V/
Q.
Table 1 reports the matching results for all three patients
with COPD considered. From Table 1, it is clear that the
models are closely matched to the data with percentage
errors below or around 1%. In order to assess the robust-
ness of subsequent findings, 100 random parameter sets
within 65% of the best fit for each patient were also gener-
ated. All the analyses described below were applied to the
best-fit model, and findings were subsequently checked for
consistency on all 100 parameter sets around each optimal
patient parameter set.
Modeling of drug effects and application methods
The change from baseline of PVR after drug administra-
tion was used as an input for the model. In order to spe-
cifically simulate the behavior of riociguat, the respective
mean relative PVR curve, as measured for a dose of
2.5 mg riociguat,31 was considered for the present simula-
tions (see Figure 1). Individual data on PVR changes
after treatment with riociguat were not published in ref. 31
and, therefore, the same mean profile was used for all
simulated patients.
In the simulator, the pulmonary vessels are modeled as a
parallel network with 100 compartments. Each compart-
ment has a vascular resistance denoted as PVRi, and the
total pulmonary vascular resistance is defined as:
PVRtot5
1
1
PVR1
1 1PVR21   1 1PVR100
(1)
Thus, reduction of PVR is captured by changing the
resistances of individual compartments due to drug admin-
istration. For a given temporal profile of the drug-induced
change of PVR (see Figure 1), the temporal changes of
PVRi in the individual compartments are calculated as
follows.
After systemic application, the drug substance is deliv-
ered to the lungs through the blood circulation. The
assumption in this case is that the drug will act equally on
all compartments with blood going through them, and pro-
duce the same amount of vascular resistance reduction:
PVRi tð Þ5PVRbaselinei 2a tð Þ  DPVR (2)
where DPVR is a fixed value denoting the equal reduction in
resistance for all compartments, and a tð Þ is a time-
dependent variable reflecting the variability of the drug
effects over time. Combining Eq. 1 and Eq. 2, the desired
PVR reduction shown in Figure 1 can be straightforwardly
implemented by adjusting a.
In the case of inhaled application of an aerosol, for exam-
ple, containing the drug, we assume that deposition of the
drug in different compartments of the lungs is proportional
to the extent of ventilation in these compartments. This
means that the drug only reaches compartments of the
lungs that are ventilated under normal breathing conditions.
In addition, it is assumed that an inhaled application will not
lead to systemic exposure causing any systemic effect, nor
any effect in the parts of the lungs not directly addressed
via inhalation.
Table 1 Patient matching results
Patient 1 Patient 2 Patient 3
Data Model Error Data Model Error Data Model Error
PaO2, mmHg 129.2 129.3 0.08% 76.8 76.69 0.14% 66.0 65.5 0.76%
PaCO2, mmHg 44.1 44.12 0.05% 49.8 49.85 0.10% 32.5 32.3 0.62%
Dead space, % 45.8 45.8 0.00% 39.9 39.8 0.25% – 40.0 –
0.001<V/Q<0.1% 33.1 33.2 0.30% 13.6 13.61 0.07% – 22.4 –
0.1<V/Q<10% 63.7 64.4 1.10% 84.9 84.29 0.72% – 75.1 –
PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of oxygen; V/Q, ventilation-perfusion.
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Figure 1 Mean change of pulmonary vascular resistance (PVR)
from baseline over time in patients receiving a single dose of rio-
ciguat 2.5 mg.
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Despite the assumption that the drug reaches only venti-
lated areas, and, thus, only in a part of the lungs will a vas-
odilatory effect be induced, we assume that a similar
reduction of total PVR is achievable as observed with the
systemic application (Figure 1). This assumption is sup-
ported by the fact that for inhaled iNO PVR reductions in
the range of 25–30% were observed.18,22,23 Furthermore, it
is assumed that the inhalation process is short, compared
to the absorption and induction effect and, thus, the time
course of the PVR reduction would be the same as the one
observed after oral administration (Figure 1). Furthermore,
it is assumed that the drug effect is proportional to the
amount of drug deposited. Accordingly, the changes in vas-
cular resistance due to treatment with the drug for each
compartment is proportional to the ventilation reaching that
compartment, and consequently the changed resistance
PVRi is given by:
PVRi tð Þ5PVRbaselinei 12b tð Þ  DPVRið Þ (3)
where DPVRi5VTi=VT , b tð Þ reflects the temporal effect of
the drug, VTi is the ventilation of alveolar compartment i,
and VT is the total tidal volume. Combining Eq. 1 and
Eq. 3, the desired PVR reduction in Figure 1 can be imple-
mented straightforwardly by adjusting b.
Independent of the application device, DPI always needs
a deep breath for inhaling the drug dose. Deep inhalation
causes a rapid increase of lung volume, which results in
dilating of the airway and a temporary reduction of airway
resistance,41,42 which will affect how the drug is delivered.
We model the effect of this reduction of airway resistance,
with the underlying assumption that compartments with
larger initial volumes will exhibit smaller reductions in airway
resistance. Given that total parallel airway resistance Raw is
given by:
Raw5
1
1
Raw1
1 1Raw21   1 1Raw100
(4)
the new airway resistance for compartment i is then given
by:
R awi5Rawi  Dawi; where Dawi5 1
11 XawVoli
(5)
where Voli is the volume of compartment i, and Xaw is a
scaling parameter related to tidal volume. It can be seen
that a smaller Voli will lead to a bigger reduction of airway
resistance. For example, setting Xaw5 20, we have that:
(1) if Voli520 mL, Dawi50.5; and (2) if Voli5 80 mL,
Dawi5 0.8. The deep inhalation is replicated in the virtual
patients by applying a threefold increase in tidal volume for
a period of five respiratory cycles.
In patients with COPD, oxygen consumption (VO2) is
more restrained by impaired pulmonary ventilation than by
oxygen delivery, which imposes exercise limitations upon
these patients. Under exercise, VO2 for patients with COPD
has been shown to increase to 0.7 L.min21 (SD5 0.25), on
average.43,44 In response to the elevated VO2, minute venti-
lation and cardiac output rise accordingly to deliver more
oxygen to the tissues.44,45 In our model, the physiological
effects of initiating exercise were simulated by progressively
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Figure 2 Values for tidal volume and respiratory rate as well as the corresponding changes to partial pressure of oxygen (PaO2) and
partial pressure of carbon dioxide (PaCO2) at rest and under exercise.
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increasing VO2 every minute to 0.35, 0.5, 0.6, 0.65, and
0.7 L.min21 in the virtual patients. Minute ventilation was
subsequently increased as required to maintain the arterial
blood gases at their pre-exercise values, using the expo-
nential relation between tidal volume and respiratory rate in
ref. 46. Cardiac output was raised to 8.2 L.min21 according
to the average change observed in ref. 44, and following
the increase in cardiac output an additional 10% reduction
in PVR to that caused by the drug was applied.46 Exercise
was simulated to start 30 minutes after administration of
the drug by inhalation with deep breath and continues for
90 minutes. The at-rest and under-exercise values for tidal
volume and respiratory rate as well as the corresponding
changes to PaO2 and PaCO2 due to exercise are presented
in Figure 2.
RESULTS
Systemic application
The average PVR reduction profile observed with 2.5 mg
riociguat was applied to the three configured virtual patients
with COPD for each of the three application methods (sys-
temic, inhaled, and DPI). The changes in gas exchange
parameters, PaO2, and PaCO2 over time were then
recorded, and are shown for each patient in Figure 3a,b. In
the case of systemic application, reductions in PaO2 and
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Figure 3 Simulation results for patients using different drug administration methods. PaCO2, partial pressure of carbon dioxide; PaO2,
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increases in PaCO2 were observed for all three patients.
For systemic application, the average percentage change
for PaO2 is 224.1% and for PaCO2 is 19.2%, which are
consistent with results reported in a previous clinical study
with riociguat.31
Inhaled application
In contrast to the systemic application, an inhaled adminis-
tration leads to considerable improvements in oxygenation,
as shown in Figure 3g,h. The maximum increases of
PaO2 are 20.2%, 6.3%, and 6.8% with an average of
11.1%, whereas the maximum decreases of PaCO2 are
219.7%, 211.2%, and 28.2%, respectively, with an aver-
age of 213.0%. This is as expected, because, in this case,
no deep breaths are required on the part of the patients
and, thus, the entire compound is delivered only to the nor-
mally ventilated regions of the lungs.
Dry powder inhaler application at rest and under
exercise
Figure 3c,d shows the effects of application of the same
compound using DPI via a deep breath at rest, which is a
more realistic scenario for an inhaled therapy in COPD.
With the same PVR reduction profile, changes of blood gas
values are in between those calculated for the systemic
and continuous inhaled applications. In fact, it can be seen
that PaO2 is slightly increased and PaCO2 is slightly
reduced for all three patients. The maximum increases of
PaO2 are 1.6%, 1.5%, and 1.7%, respectively, with an aver-
age of 1.6%. The maximum changes of PaCO2 are 0.0%,
0.1%, and 20.7%, respectively, with an average of 20.2%.
Figure 3e,f shows that undertaking exercise for 1 hour
after application by DPI produces further improvements in
oxygenation, with maximum increases of PaO2 of 5.1%,
0.8%, and 2.4% with an average of 2.8%, and maximum
decreases of PaCO2 of 22%, 23.3%, and 22.5%, respec-
tively, with an average of 22.6%.
Robustness analysis
To test the robustness of our results, for each patient, all
simulations (i.e., systemic application, inhalation with deep
breath at rest and under exercise, and inhalation with nor-
mal breath) were repeated on 100 parameter sets randomly
chosen within bounds of 65% of the optimal parameter set
found by means of global optimization. Figure 4 compares
the maximum change in PaO2 and PaCO2 observed for
each patient and each application method using the optimal
parameter set (squares) with the average maximum change
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Figure 4 Comparison of the maximum change in partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2)
observed for each patient and each application method using the optimal parameter set (squares) with the average maximum change
in PaO2 and PaCO2 calculated using 100 random parameter sets (circles with one SD as error bars).
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in PaO2 and PaCO2 calculated using 100 random parame-
ter sets (circles with one SD as error bars). The outcomes
confirm the consistency of the observed responses to the
different methods of drug administrations (i.e., the average
maximum change from baseline) for PaO2 and PaCO2
across all random sets for each patient closely matches the
maximum changes reported when using the optimal param-
eter set during our previous analysis. Supplementary
Figures S3–S5 show time-response plots for the performed
robustness analysis.
DISCUSSION
This is the first study to investigate the efficacy of sGC
modulators in patients with COPD with PH by using com-
puter simulation. The capability of the simulator to accu-
rately describe the pathophysiological characteristics of gas
exchange in patients with COPD has already been demon-
strated in a previous study.36 That study showed that by
including sufficient numbers of alveolar compartments in
the model, accurate representations of both steady-state
blood gases and ventilation-perfusion mismatch via V/Q
curves could be obtained. In this study, we further demon-
strated close matching of the simulator to data on three
patients whose hemodynamics was invasively monitored in
the study reported by Ghofrani et al.31 Calculations of blood
gas concentrations for these virtual patients, considering
the observed temporal profile of average PVR changes
after oral administration of riociguat, resulted in predictions
of changes in O2 and CO2 partial pressures that were con-
sistent with those observed in the previous clinical study.
These results can be considered as a strong validation of
the capability of the pulmonary simulator to reliably
describe the effects on gas exchange of compounds acting
on the vascular resistance, in particular those stimulating
the sGC activity.
As already discussed in previous publications, the sys-
temic application of vasodilating drugs may lead to a wors-
ening of V/Q mismatch and in consequence to an
impairment of blood gas concentrations, which limits their
clinical use. This arises due to the nonselective distribution
of the drug to all parts of the lungs, which together with
inhibition of hypoxic pulmonary vasoconstriction leads to an
excess of blood flowing to poorly ventilated parts of the
lungs.
One potential way to avoid increases of V/Q mismatch is
via inhaled administration, as long as the drug can be
expected to only reach the ventilated parts of the lungs.
This avoids increasing the perfusion of nonventilated lung
compartments, provided systemic exposure stays low
enough after inhalation not to be effective. Our results from
simulations based on this scenario with inhalation of a
hypothetical sGC modulating drug, which can be applied to
act on the lung selectively, supports this hypothesis when it
is administered by normal breathing. In contrast to the find-
ings from systemic administration, the inhaled application
led to improved oxygenation, because perfusion of venti-
lated lung compartments was improved and effects on less
well/nonventilated areas were limited. However, if the drug
is formulated as a dry powder, its inhalation will usually be
connected with a deep breath, which could cause a certain
proportion of the compound to be deposited in regions of
the lungs that are not, or poorly, ventilated when returning
to normal breathing at rest. To quantitatively investigate the
trade-offs involved, we also modeled the effect of inhaled
administration of a compound inducing the same effect on
total PVR as 2.5 mg oral riociguat in COPD-PH with a
deep breath, causing the temporary recruitment of less well
ventilated areas. The resulting simulations reveal that,
although administering the drug by a deep breath may not
improve oxygenation to the same extent as inhalation with
normal breathing, it does avoid the potential deterioration in
gas exchange associated with systemic drug administra-
tion. Moreover, when administered under exercise, most of
the non/poorly ventilated parts of the lungs in which the
drug is deposited due to deep breathing become ventilated
again as a result of increased minute ventilation, leading to
further improvements in oxygenation. Interestingly, these
findings are also in agreement with the results of a clinical
trial on the systemic administration of the PDE-5 inhibitor
sildenafil, which produced a worsening of gas exchange
due to increased V/Q mismatching at rest, but not under
exercise.13
A robust analysis of these results performed by means of
randomly selecting 100 model parameter sets around the
optimal values for each patient produced results that were
uniformly consistent with the above findings. Our results
highlight the potential advantages of administering sGCs to
patients via DPI, rather than systemically, particularly when
drug administration is combined with exercise.
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